Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Barclays upgrades Wizz Air to 'overweight', shares soar

(Sharecast News) - Wizz Air shares soared on Friday after Barclays upgraded the airline to 'overweight' from 'equalweight' and lifted the price target to 1,500p from 1,100p, "substantially reflecting" a higher assumed mid-term EBIT margin, increased from 6.5% to 7.8%. "For context our £15 price target would represent a 5.7x price-to-earnings on our revised FY28 earnings," the bank said.

"We recognise that there will be a significant period of uncertainty until the fleet renegotiation is defined."

It noted that Wizz plans to present a new business plan to the market towards the end of this year.

"We further expect unit costs to be challenged by the costs of slowing growth and the share to be burdened by falling consensus for FY26," it said. "The financial consequences of poor recent decision-making will not vanish with a set of better decisions in recent weeks.

"However, we see a far brighter future for a Wizz that grows modestly, focussing on its core CEE market, where it enjoys a strong market position. We expect sentiment on the stock to inflect to the positive."

At 1225 BST, the shares were up 8.9% at 1,169p.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.